Ms. Wu Xia (吴夏), aged 42, is a non-executive Director. She was appointed as a non-executive Director on August 5, 2019 and is mainly responsible for participating in decision-making of important matters of our Group and the high-level oversight of the management and operations of our Group. Ms. Wu also serves as a director of MP CardioFlow since she joined our Group in October 2017.

Ms. Wu has over 12 years of experience in research and private equity investment focusing on healthcare industry. She is currently serving as a managing director of CICC Capital Management Co., Ltd. (中金资本运营有限公司) (“CICC Capital”) since January 2019 and is responsible for the overall investment and management of CICC Kangrui. Ms. Wu joined CICC Jia Cheng Investment Management Company Limited (中金佳成投资管理有限公司) in July 2008 and served as vice president from January 2012 to December 2014 and as executive director from January 2015 to August 2018. In August 2018, Ms. Wu transferred into CICC Capital as executive director. Ms. Wu has been a director of Genetron Holdings Limited (a company listed on the NASDAQ under the trading symbol of “GTH”) since September 2017. Ms. Wu has been a non-executive director of MicroPort NeuroTech Limited (微创脑科学有限公司) (a company incorporated in the Cayman Islands with limited liability whose shares are listed on the Main Board of the Stock Exchange (stock code: 2172)) since November 2021.

Ms. Wu obtained her bachelor’s degree in finance from Peking University (北京大学) in China in July 2003, and a master’s degree in economics and finance from Warwick Business School of the Warwick University in the United Kingdom in January 2005. She was honored “Outstanding Young PE Investor of the Year 2018” by China Renaissance (华兴资本) in 2018.